PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1876810
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1876810
Peptide Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
The Global Peptide Therapeutics Market was valued at USD 46.4 billion in 2024 and is estimated to grow at a CAGR of 8.1% to reach USD 100 billion by 2034.
The increasing prevalence of chronic and lifestyle-related diseases, including diabetes, cancer, and obesity, is a significant growth driver. Peptide therapeutics, composed of short chains of amino acids, target specific molecular pathways, offering high efficacy and reduced side effects compared to conventional therapies. These treatments are applied across diverse therapeutic areas such as metabolic disorders, cardiovascular diseases, gastrointestinal conditions, infectious diseases, cancer, and rare genetic disorders. The integration of electronic health records, AI-based clinical decision-making tools, and real-world evidence platforms is reshaping the development, monitoring, and prescription of peptide therapies. Government programs and public-private partnerships enhancing access to molecular diagnostics, personalized medicine, and rare disease treatments further accelerate growth. With rising demand for biologically inspired and precision medicines, peptide therapeutics are emerging as critical solutions in modern healthcare due to their safety, specificity, and wide-ranging therapeutic potential.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $46.4 Billion |
| Forecast Value | $100 Billion |
| CAGR | 8.1% |
The branded peptides segment held a 69.2% share in 2024, driven by its strong focus on innovation, high specificity, and proven clinical efficacy. These therapies are increasingly preferred for the treatment of complex and chronic conditions, where precise targeting and minimal off-target effects are essential. Branded peptides benefit from robust research and development pipelines, continuous formulation improvements, and advanced delivery mechanisms, which enhance patient outcomes and therapeutic reliability.
The parenteral segment generated USD 30.8 billion in 2024, owing to the poor stability and low oral bioavailability of peptides, making intravenous, subcutaneous, or intramuscular administration the preferred delivery method. Parenteral delivery ensures rapid absorption, accurate dosing, and high efficacy for critical indications such as metabolic disorders, cancer, and rare endocrine conditions.
North America Peptide Therapeutics Market held a 42.1% share in 2024. Growth in the region is fueled by advanced biopharmaceutical infrastructure, early regulatory approvals, strong R&D investments, and the rising prevalence of cancer, metabolic disorders, and rare diseases. The development of branded and innovative peptide therapies in countries like the U.S. and Canada supports demand for targeted, low-toxicity treatments.
Key players in the Global Peptide Therapeutics Market include Novo Nordisk, PolyPeptide Group, Rhythm Pharmaceuticals, Ascendis Pharma, Zydus Lifesciences, Ferring Pharmaceuticals, AstraZeneca, X-GEN Pharmaceuticals, Eli Lilly and Company, Repligen Corporation, Sanofi, Amgen, Bristol-Myers Squibb, PeptiDream, and Merck & Co. Companies in the Peptide Therapeutics Market are adopting strategies such as investing in research and development to create novel peptide formulations, collaborating with biotech startups to accelerate innovation, and forming strategic alliances for global distribution. Many firms focus on expanding their product portfolios to cover rare and chronic diseases while enhancing manufacturing capabilities for high-purity peptides. Market participants are increasingly leveraging digital platforms and AI for precision drug development, patient monitoring, and real-world data collection.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/country
- 1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumption and limitations
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
- 2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Type trends
- 2.2.3 Application trends
- 2.2.4 Route of administration trends
- 2.2.5 Manufacturer type trends
- 2.2.6 Synthesis technology trends
- 2.2.7 End use trends
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Value addition at each stage
- 3.1.3 Factor affecting the value chain
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of cancer
- 3.2.1.2 Rising incidences of metabolic & endocrine disorders
- 3.2.1.3 Increasing investments in research and development of novel drugs
- 3.2.1.4 Technological advancement in peptide therapeutics
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Stringent regulatory requirements for drug approval
- 3.2.2.2 High cost for drug development
- 3.2.3 Market opportunities
- 3.2.3.1 Innovation in peptide-drug conjugates and radiolabelled peptides
- 3.2.3.2 Expansion of oral and long-acting peptide formulations
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.4.4 Latin America
- 3.4.5 Middle East and Africa
- 3.5 Future market trends
- 3.6 Technological landscape
- 3.6.1 Current technologies
- 3.6.2 Emerging technologies
- 3.7 Patent analysis
- 3.8 Pipeline analysis
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Branded peptides
- 5.3 Generic peptides
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Metabolic & endocrine disorders
- 6.3 Cancer
- 6.4 Cardiovascular disorders
- 6.5 Gastrointestinal disorders
- 6.6 Central nervous system disorders
- 6.7 Respiratory disorders
- 6.8 Pain management
- 6.9 Other applications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Parenteral
- 7.3 Oral
- 7.4 Other route of administration
Chapter 8 Market Estimates and Forecast, By Manufacturer Type, 2021 - 2034 ($ Mn)
- 8.1 Key trends
- 8.2 In-house
- 8.3 Outsourced
Chapter 9 Market Estimates and Forecast, By Synthesis Technology, 2021 - 2034 ($ Mn)
- 9.1 Key trends
- 9.2 Liquid phase peptide synthesis (LPPS)
- 9.3 Solid phase peptide synthesis (SPPS)
- 9.4 Hybrid technology
Chapter 10 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)
- 10.1 Key trends
- 10.2 Hospitals and clinics
- 10.3 Pharmaceutical and biotechnology companies
- 10.4 Other end use
Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
- 11.1 Key trends
- 11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Netherlands
- 11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 South Korea
- 11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Argentina
- 11.6 Middle East and Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 UAE
Chapter 12 Company Profiles
- 12.1 Amgen
- 12.2 Ascendis Pharma
- 12.3 AstraZeneca
- 12.4 Bristol-Myers Squibb
- 12.5 Eli Lilly and Company
- 12.6 Ferring Pharmaceuticals
- 12.7 Merck & Co.
- 12.8 Novo Nordisk
- 12.9 PeptiDream
- 12.10 PolyPeptide Group
- 12.11 Repligen Corporation
- 12.12 Rhythm Pharmaceuticals
- 12.13 Sanofi
- 12.14 X-GEN Pharmaceuticals
- 12.15 Zydus Lifesciences
